US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

(Stockholm, 8 June 2021.) The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in a raft of stress-related disorders, from Tourette to OCD, characterized by tics and compulsions. Sepranolone is essentially patented isoallopregnanolone, the endogenous compound that inhibits ALLO. This patent confirms Sepranolone’s enormous clinical potential.”The new patent is valid until 2038.

Asarina Pharma AB (publ) Q3 2020 report released

Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. We remain confident of completing both studies on schedule, so realizing our vision of bringing a new treatment modality to market for under-treated conditions that can help millions remain in control of their lives.”FINANCIAL HIGHLIGHTS · R&D costs at same level as in Q2, 2020 · Reduction in G&A and

Asarina Pharma AB (publ) Interim Report Q2 2020 released

Asarina Pharma CEO Peter Nordkild: “The second Quarter 2020 has given us continued proof of the urgent need for new, safe and effective treatments for the devastating conditions that our flagship compound, Sepranolone, targets. Despite disappointing results in our Phase IIb PMDD study at the beginning of the Quarter, which we covered extensively in our Q1 Interim Report, this second Quarter powerfully underlined the unmet need for new, safe, effective treatments for menstrual migraine and Tourette Syndrome.”FINANCIAL HIGHLIGHTS · Decrease in R&D costs after completion of PMDD study ·

First patient dosed in landmark Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.Globally, three times more women than men suffer from migraine. Approximately 50 million of those also suffer from menstrual migraine, a more severe form highly resistant to standard treatments, including recently developed CGRP antibodies. Sepranolone is the first compound to target this highly frequent form of female migraine. If

Asarina Pharma: Redeye reports positively on new directed share issue

October 25, 2019: Redeye: “We see Asarina Pharma as one of the truly undiscovered biotech cases on the Scandinavian stock markets. We argue that the prospects for showing good results in its PMDD Phase IIb Study are good, which is not at all reflected in the stock price at present.”On October 24 Asarina Pharma (publ) (ASAP) announced a new, directed share issue worth approximately 48 MSEK. Subscribers include Handelsbanken, Sweden’s Fourth AP Fund, Swedbank Robur and Östersjöstiftelsen. Asarina Pharma CEO Peter Nordkild: “We're proud major long-term Swedish investors like Fourth AP Fund,

Asarina Pharma AB (publ) Interim Report Q2 2019 released

Asarina Pharma CEO Peter Nordkild: “This has been a Quarter of important milestones: last patient in for our Phase IIb PMDD study, FDA approval of our IND for Sepranolone, Clinical Trial Approval for our Phase IIa Menstrual Migraine study and growing interest from future potential partners.”FINANCIAL HIGHLIGHTS 1 April – 30 June 2019 TOTAL OPERATING COSTS SEK 28.1M (11.5M) NET RESULT -25.8M (-9.7M) CASH AND CASH EQUIVALENTS (30 JUNE 2019): SEK 109.5M (9.7M) SIGNIFICANT EVENTS DURING THE SECOND QUARTER WHO classification of PMDD In May PMDD (Premenstrual Dysphoric Disorder)

Last Patient In for landmark PMDD study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the last patient was enrolled in the Phase IIb study for its first-in-class compound Sepranolone for premenstrual dysphoric disorder (PMDD). Top-line results are on track for late March 2020.“This is a crucial milestone. Full enrolment means we are on track to deliver top-line results in late March 2020 as promised. It also shows how large the unmet need and market potential is. PMDD is a devastating disorder afflicting 1-in-20 women of reproductive age worldwide,” said CEO Peter Nordkild.   Sepranolone reduced key symptoms by

Sepranolone receives FDA IND approval in menstrual migraine

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile.“The FDA IND approval in menstrual migraine is an important validation of the strong safety profile of our compound and also has very positive implications for our upcoming larger clinical PMDD trials.” said Peter Nordkild, CEO of Asarina Pharma. “All preclinical and clinical data on Sepranolone, over 100 documents in all, were submitted to the FDA for review and

Asarina Pharma Year-End Report 2018 shows solid progress

Stockholm, 25 February, 2019: Asarina Pharma AB releases its Year-End Report including financials for the fourth quarter 2018 and for the full year 2018. (READ THE FULL YEAR-END REPORT IN PDF HERE .)Fourth Quarter 2018: FINANCIAL HIGHLIGHTS · Net sales amounted to 0 (0) kSEK                                        · Operating loss was - – 20,481 (-7 364) kSEK                      · Loss per share, before dilution, SEK -0.88 (-0.45) · On 31 December 2018 Asarina had total cash and cash equivalents of 141

Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial

Stockholm – December 18, 2018. On December 17 Asarina Pharma’s Scientific Advisory Board (SAB) gave its full backing to the company’s upcoming trial of a new preventive treatment for Menstrual Migraine. The SAB comprises world-leading independent scientists in obstetrics, gynaecology, neurology and pharmacology, including Prof Anne MacGregor, one of the world’s foremost authorities on headache and migraine.Migraine is more prevalent than diabetes, epilepsy and asthma combined, three times more women than men suffer from it, and 1-in-5 of those suffer from menstrual migraine. Yet currently

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe